Colorectal Cancer Trial, Recruiting (NCT06549907)

Colorectal Cancer Trial, Recruiting NCT06549907 Sponsor: Peking University Cancer Hospital & Institute Condition: Colorectal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06549907 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Colorectal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a specific type of colorectal cancer that has spread (called MSS metastatic colorectal cancer), confirmed by laboratory testing, and it has stopped responding to a type of immunotherapy drug that targets PD1/PDL1
Alternatively, you have a different type of solid tumor (called MSI) that has also stopped responding to PD1/PDL1 immunotherapy drugs
You are currently receiving a combination treatment that includes two types of immunotherapy (targeting both PD1/PDL1 and CTLA4) together with a treatment that targets blood vessel growth (anti-angiogenic therapy), with or without additional other treatments

Who may not be able to join:

You have an active cancer outside of the digestive system that has not been cured or successfully treated (note: people with Lynch syndrome are not automatically excluded by this rule — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jian Li, Peking University Cancer Hospital & Institute

Phone: 18813186790

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06549907

Sponsor: Peking University Cancer Hospital & Institute

Phase: Not Applicable

Status: Recruiting

Condition: Colorectal Cancer

Trial contact: 18813186790

More information: https://clinicaltrials.gov/study/NCT06549907

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a specific type of colorectal cancer that has spread (called MSS metastatic colorectal cancer), confirmed by laboratory testing, and it has stopped responding to a type of immunotherapy drug that targets PD1/PDL1
Alternatively, you have a different type of solid tumor (called MSI) that has also stopped responding to PD1/PDL1 immunotherapy drugs
You are currently receiving a combination treatment that includes two types of immunotherapy (targeting both PD1/PDL1 and CTLA4) together with a treatment that targets blood vessel growth (anti-angiogenic therapy), with or without additional other treatments

Who may not be able to join:

You have an active cancer outside of the digestive system that has not been cured or successfully treated (note: people with Lynch syndrome are not automatically excluded by this rule — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University Cancer Hospital & Institute

Registry

ClinicalTrials.gov

Start date

10 January 2024

Est. completion

30 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Baseline proportion and location of different immune cell subsets associated with efficacy; Baseline tumor gene alterations associated with efficacy; Baseline clinical characteristics associated with efficacy; Baseline tumor-associated proteins associated with efficacy; Baseline intestinal flora associated with efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov